Evidence map›Paper›PMID 25027514›Full record

ArticleLeukemia2014

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.

C P Venner, J D Gillmore, S Sachchithanantham, S Mahmood, T Lane, D Foard, L Rannigan, S D J Gibbs, J H Pinney, C J Whelan and 3 more

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03401372 (Comparison of Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy With or Without Doxycycline in Newly Diagnosed Mayo Stage II-III Light Chain Amyloidosis Patients), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03401372 nacompletednot on this mapstarted 2018, after this paper: background citation

Comparison of Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy With or Without Doxycycline in Newly Diagnosed Mayo Stage II-III Light Chain Amyloidosis Patients: A Multi-center Randomized Controlled Trial

TypeinterventionalSponsorJian LiRan2018 to 2020Enrolled140ConditionsAmyloidosis, SystemicArmsDoxycycline, Bortezomib, Cyclophosphamide, Dexamethasone
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Review
  14. Novel Therapies in Light Chain Amyloidosis.Kidney international reports · 2018
    Review
  15. The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018
    Article
  16. Cardiac amyloidosis.Clinical medicine (London, England) · 2018
    Review
  17. Review
  18. Light Chain Amyloidosis.Mediterranean journal of hematology and infectious diseases · 2018
    Review
  19. AL amyloidosis: from molecular mechanisms to targeted therapies.Hematology. American Society of Hematology. Education Program · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

C P Venner1] National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK [2] Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
J D GillmoreNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
S SachchithananthamNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
S MahmoodNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
T LaneNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
D FoardNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
L RanniganNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
S D J Gibbs1] National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK [2] Department of Clinical Haematology, Manchester Royal Infirmary, Central Manchester University Hospitals, Manchester, UK.
J H PinneyNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
C J WhelanNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
H J LachmannNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
P N HawkinsNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
A D WechalekarNational Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Hospital Campus, London, UK.
University College London · GBThe Royal Free Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite improvements in therapy amyloid light-chain (AL) amyloidosis, there are few studies comparing different regimens. Here we present a matched comparison with 69 patients in each cohort examining upfront therapy with cyclophosphamide, bortezomib and dexamethasone (CVD) vs cyclophosphamide, thalidomide and dexamethasone (CTD). On an intention-to-treat basis, the overall response rates were 71.0% vs 79.7% in the CVD and CTD arms, respectively, (P=0.32). A higher complete response (CR) rate was observed in the CVD arm (40.5%) vs CTD (24.6%), P=0.046. One-year overall survival (OS) was 65.2% and 66.7% for CVD and CTD, respectively (P=0.87). The median progression-free survival (PFS) was 28.0 and 14.0 m for CVD and CTD, respectively (P=0.039). In a landmark analysis assessing outcomes performed at 6 months, the CR rate with CVD was 59.6% vs 34.0% for CTD (P=0.03). The 1-year OS was 96% with CVD and 92% with CTD (P=0.40). The median PFS with CVD was not reached and was 19.2 m with CTD, P=0.028). In summary, both regimens are unable to overcome the high rate of early deaths in AL amyloidosis. However, CVD correlates with improved depth of response and superior PFS supporting its use in the frontline setting. Further optimisation and better supportive-care strategies are required to increase the proportion of patients fully benefiting from therapy.

Indexed as

AdultAgedAged, 80 and overAmyloidosisAntineoplastic Combined Chemotherapy ProtocolsBoronic AcidsBortezomibCohort StudiesCyclophosphamideDexamethasoneFemaleFollow-Up StudiesHumansImmunoglobulin Light ChainsMaleMiddle AgedBoronic AcidsBortezomibCyclophosphamideDexamethasoneImmunoglobulin Light ChainsPyrazinesThalidomide

Identifiers

PMID25027514
OpenAlexW2012680794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.